January 29, 2018 / 12:11 PM / 10 months ago

BRIEF-Antibe Announces Enrollment In Mid-Stage Trial of Pain Drug ATB-346

Jan 29 (Reuters) - Antibe Therapeutics Inc:

* ANTIBE THERAPEUTICS ANNOUNCES ENROLLMENT OF FINAL SUBJECTS IN PHASE 2B GASTROINTESTINAL SAFETY STUDY OF LEAD PAIN DRUG, ATB-346 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below